Skip to main content
Fig. 1 | Journal of Nanobiotechnology

Fig. 1

From: Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer

Fig. 1

The detection of multidrug resistance genes and the multidrug resistance gene siRNA sequence. A Images illustrating cytotoxicity in 510K versus 510 cells using increasing concentrations of Adriamycin (0.5–8 µg/ml). Scale bar, 100 µm. B Spectrophotometric analysis showing cytotoxicity of Adriamycin at the variable concentration on 510K and 510 cells (mean ± s.e.m., n = 3). C Transcription levels of the five MDR genes in 510K and 510 cells (mean ± sem,n = 3). D, E The efficiency of silencing MVP and BCL2-mRNA by designed sequences of MVP-siRNAs D and BCL2-siRNAs E (mean ± sem, n = 3). F, G MVP and BCL2 protein expression by designed MVP-siRNAs (F) and BCL2-siRNAs (G). NS: no significant difference. *p < 0.05, double-tailed t-test

Back to article page